The relevance of monitoring lamotrigine serum concentrations in chronic pain patients

Acta Neurologica Belgica

Volumn 106, Issue 1, 2006, Pages 15-18

  Devulder, Jacques ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anticonvulsants; Complications; Lamotrigine; Pain relief; Plasma serum concentrations

Indexed keywords

CYTOCHROME P450; LAMOTRIGINE;

ADULT; AGED; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CHRONIC PAIN; CLINICAL ARTICLE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG METABOLISM; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEUROPATHIC PAIN; NOCICEPTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33744501824     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bialer M. The pharmacokinetics and interactions of new antiepileptic drugs: an overview. Ther. Drug Monit., 2005, 27: 722-726.
2. Choi H., Morrell M. J. Review of lamotrigine and its clinical applications in epilepsy. Expert Opin. Pharmacotherapy, 2003, 4: 243-51.
3. Garnett W. Lamotrigine: pharmacokinetics. J. Child Neurol., 1997, 12 (S1): S10-S15 .
4. Grünze H., Wegerer J., Greene W., Walden J. Modulation of Calcium and Potassium Currents by Lamotrigine. Neuropsychobiology, 1998, 38: 131-138.
5. Hirsch L., Weintraub D., Du Y., Buchsbaum R., Spencer H. et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology, 2004, 63: 1022-1026.
6. Johannessen S., Battino D., Berry D., Bialer M., Kramer G. et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit., 2003, 25: 347-363.
7. Ketter T., Wang P., Chandler R., Alarcon A., Becker O. et al. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. J. Clin. Psychiatry, 2005, 66: 642-645.
8. May T., Rambeck B., Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther. Drug Monit,, 1996, 18: 523-531.
9. Neels H., Sierens A., Naelaerts K., Scharpé S., Hatfield G. et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin. Chem. Lab. Med., 2004, 42: 1228-1255.
10. Patsalos P., Froscher W., Pisani F., van Rijn C. The importance of drug interactions in epilepsia. Epilepsia, 2002, 43: 365-385.
11. Peck A. Clinical pharmacology of lamotrigine. Epilepsia, 1991, 32 (S2): S9-S12.
12. Perruca E. The clinical pharmacology of the new antiepileptic drugs. Pharmacol. Research, 1993, 28: 89-106.
13. Sbei M., Campellone J. Stupor from Lamotrigine toxicity. Epilepsia, 2001, 42: 1082-1083.
14. Schaub J., Williamson P., Barnes E., Trewby P. Multisystem adverse reaction to lamotrigine. Lancet, 1994, 344: 481.
15. Sindrup H. J., Jensen T. S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain, 1999, 83: 389-400.
16. Tuchman M., Broadstone V., Blum D., Silver M., Grainges J. et al. 11th world congres on pain Sydney 2005, Abstract book p. 211.
17. Wadelius M., Karlsson T., Wadelius C., Rane A. Lamotrigine and toxic epidermal necrolysis. Lancet, 1996, 348: 1041.
18. Wilkinson G. Drug metabolism and variability among patients in drug response. N. Engl. J. Med., 2005, 352: 2211-2221.